Intravenous lidocaine for fibromyalgia syndrome: an open trial

Fibromyalgia is a disorder characterized by chronic widespread pain. In this study, we investigated the effect of intravenous infusions of lidocaine in pain and quality of life of patients with fibromyalgia. Twenty-three consecutive patients were included in the study, which consisted on five sequen...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2009-07, Vol.28 (7), p.853-855
Main Authors: Schafranski, Marcelo Derbli, Malucelli, Tiago, Machado, Fabíola, Takeshi, Hélcio, Kaiber, Flávia, Schmidt, Carolina, Harth, Fabielle
Format: Article
Language:English
Subjects:
Adult
Anesthetics, Local - administration & dosage
Anesthetics, Local - therapeutic use
Brief Report
Female
Fibromyalgia - complications
Fibromyalgia - drug therapy
Fibromyalgia - physiopathology
Health Status
Humans
Infusions, Intravenous
Lidocaine - administration & dosage
Lidocaine - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Pain
Pain - etiology
Pain - physiopathology
Pain - prevention & control
Pain Measurement
Quality of Life
Rheumatology
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fibromyalgia is a disorder characterized by chronic widespread pain. In this study, we investigated the effect of intravenous infusions of lidocaine in pain and quality of life of patients with fibromyalgia. Twenty-three consecutive patients were included in the study, which consisted on five sequential intravenous 2% lidocaine infusions with rising dosages (2-5 mg/kg, days 1-5). Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire, and a visual analog scale (VAS) for pain were applied before the first lidocaine infusion, immediately after the fifth infusion and 30 days after the fifth infusion. A significant improvement was observed in the FIQ scores after the fifth infusion (73.52 ± 16.56 vs 63.29 ± 21.21, p = 0.02), which was maintained after 30 days (73.52 ± 16.56 vs 63.85 ± 24.59, p = 0.04). Similar results were seen concerning the VAS: 8.19 ± 1.76 vs 6.84 ± 2.44, p = 0.01 and 8.19 ± 1.76 vs 7.17 ± 2.35, p = 0.05, respectively. Intravenous lidocaine infusions are safe and effective in the management of fibromyalgia.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-009-1137-8